AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04744181 — intervention group
Intervention type: DRUG
Intervention: B vitamin
Description: administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
Study NCT04744181 — intervention group
Intervention type: DRUG
Intervention: Folic acid
Description: administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
Study NCT05819853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product (Wegovy and/or Ozempic)
Description: 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
Study NCT06311656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fasted
Study NCT06311656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fasted.
Study NCT06311656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fed and fasted.
Study NCT06311656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04931459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU193
Description: Intravenous ACU193
Study NCT04931459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo
Study NCT04183738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.
Study NCT04183738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.
Study NCT04183738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg tablet by mouth once daily for 96 weeks.
Study NCT05393271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.
Study NCT05310344 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel and bevacizumab
Description: Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
Study NCT04313036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: 25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for >/= 21 days or per discretion of enrolling physician.
Study NCT03652870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: A medication used to treat conditions such as depression
Study NCT03652870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: A medication used to treat conditions such as depression
Study NCT03652870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose and magnesium stearate tablet to be used as a placebo.
Study NCT04725617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard smoking cessation treatment.
Study NCT04725617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Standard smoking cessation treatment
Study NCT04725617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Approach 1 to Reduce Smoking
Description: Behavioral health intervention option 1
Study NCT04725617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Approach 2 to Reduce Smoking
Description: Behavioral health intervention option 2
Study NCT06139159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach/navigator
Description: * Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~* Document outreach, screening, and referral activities in LHW database
Study NCT06139159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auxiliary to care
Description: * Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~* Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~* Reviews care plan with patient and help reduce patient and system barriers impeding psychological wellbeing~* Support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~* Engage, activate, and empower patients to participate in the care process~* Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Assist with group sessions: affinity groups~* Identify community-based resources.~* Document outreach, screening, referral, and auxiliary care activities in LHW database
Study NCT06139159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped care and task shifting
Description: * Support counselling initiated by the psychologist~* Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~* Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~* Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Co-lead group sessions: affinity groups~* Provide Mental Health First Aid to members of the community.~* Document outreach, screening, referral, auxiliary and stepped care activities in LHW database
Study NCT04766047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administration of dexmedetomidine intraoperatively
Study NCT06050655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual aligners
Description: orthodontic treatment with lingual aligners
Study NCT06509750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carob-meal
Description: A meal with carob-beverage
Study NCT06509750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-carob-meal
Description: A meal with orange-beverage
Study NCT05393271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT05393271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered
Study NCT05393271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered
Study NCT05481723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: noradrenaline and vascular filling
Description: In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
Study NCT05481723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary ultrasound after vascular filling
Description: In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
Study NCT05269537 — intervention group
Intervention type: RADIATION
Intervention: Transthoracic Echocardiography
Description: Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
Study NCT05269537 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
Study NCT05269537 — intervention group
Intervention type: DRUG
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT05269537 — intervention group
Intervention type: DRUG
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study NCT05269537 — intervention group
Intervention type: DRUG
Intervention: Crystalloid Coload 1000 mL
Description: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
Study NCT05269537 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
Study NCT05269537 — intervention group
Intervention type: DRUG
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
Study NCT05269537 — intervention group
Intervention type: DRUG
Intervention: Oxytocin
Description: Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
Study NCT05542732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioWatch 287-2
Description: CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
Study NCT05233150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE/CARIÑO
Description: PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
Study NCT05563012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimal Injection
Description: Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
Study NCT05994911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness.
Study NCT05895890 — intervention group
Intervention type: GENETIC
Intervention: Sequential sampling (stool, saliva, serum) .
Description: Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
Study NCT04778059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB002
Description: USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
Study NCT04778059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
Study NCT06365008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+irinotecan+leucovorin folinate+fluorouracil
Description: sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
Study NCT05918991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Report Card
Description: Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
Study NCT05918991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Intervention
Description: The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
Study NCT05311228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Powder
Description: Azithromicyn intravena for 14 days
Study NCT06342219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback Mindfulness
Description: The participants will use a portable EEG headband (MUSE) which is a noninvasive tool for collecting EEG data. They will receive real-time EEG data given an audio feedback while doing their daily mindfulness practice.
Study NCT06342219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Task
Description: The participants in this arm will use the portable EEG while listening to an audiobook. They will receive a summary of their brain activities after task completion on each day.
Study NCT04660500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD Drivers Using AV Technologies On-road
Description: All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
Study NCT05019846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Embonate
Description: single administration before SRT starting
Study NCT05019846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Description: 1 dose each day, 7 days before LHRH until 10 days after LHRH administration
Study NCT06342011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet group
Description: Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the anti-inflammatory diet wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later.
Study NCT05156216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
Study NCT05156216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
Study NCT05583734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portomar(TM) Device
Description: Portomar(TM) access device for bone marrow biopsy
Study NCT05288595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Plus Instrument
Description: Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
Study NCT05824052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone injection
Description: Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
Study NCT04790162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heartfulness Meditation
Description: Heartfulness meditation with a trainer provided virtually
Study NCT05161455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing
Study NCT05161455 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing
Study NCT05161455 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: platelet rich fibrin
Description: we would like to measure the effect of PRF on soft and hard tissue healing
Study NCT05503602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classical Physiotherapy
Description: Only classical physiotherapy application, 5 sessions per week for 4 weeks.
Study NCT05503602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM Technique Application
Description: Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
Study NCT05503602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Roller Technique Application
Description: 2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
Study NCT04482660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with 18F-RO6958948
Description: tau PET ()